SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: more100 who wrote (324)1/16/2017 12:09:27 PM
From: DewDiligence_on_SI  Respond to of 340
 
TEVA is not just generics. In 3Q16, TEVA derived 42%(!) of its worldwide operating profits from a single branded drug—Copaxone: siliconinvestor.com (see slide #21).

With generic versions of Copaxone looming in the US market, it's no wonder that TEVA's stock has been under pressure.